论文部分内容阅读
目的:通过实验分析对急性ST段抬高型心肌梗死行PCI术患者早期应用替罗非班后的安全性及对患者心功能产生的影响,以期为今后ST段抬高型心肌梗死患者的治疗提供科学根据。方法:选取我院2014年10月~2016年10月收治100例患有急性ST段抬高型心肌梗死患者作为实验研究对象,采用随机分配法将患者分为实验组和对照组,每组50例,实验组患者入急诊室前就开始给予替罗非班,对照组在行PCI术中开始给予替罗非班,比较两组患者术前、术后血浆NT-proBNP、cTnl水平变化,左心室收缩期末、舒张期末等内径、左心室射血分数变化及术后24h及30d内不良心脏事件、出血发生率等。结果:实验组术后1周NT-proBNP下降水平明显由于对照组(P<0.01),术后24h及7d后cTnl水平下降水平明显优于对照组(P<0.01)。两组患者术后7d左心室收缩期末、舒张期末等内径差异无统计学意义(P>0.05),实验组患者左心室射血分数变化明显高于对照组(P<0.05),两组患者术后24h及30d内不良心脏事件、出血发生率等均无统计学意义(P>0.05)。结论:经试验结果显示,早期应用替罗非班对急性ST段抬高型心肌梗死行PCI术患者心功能改善效果显著,可有效提升患者左心室射血分数,且具有较高安全性,值得推广应用。
OBJECTIVE: To analyze the safety and early cardiac effects of tirofiban in patients with acute ST-segment elevation myocardial infarction who underwent early PCI and to study the effects of tirofiban on cardiac function in patients with ST-segment elevation myocardial infarction Provide scientific basis. Methods: From October 2014 to October 2016 in our hospital, 100 patients with acute ST-elevation myocardial infarction were enrolled as experimental subjects. Patients were divided into experimental group and control group by random assignment For example, patients in the experimental group started to be given tirofiban before entering the emergency room, while those in the control group were given tirofiban before PCI. The levels of NT-proBNP and cTnl in the two groups were compared before and after treatment Ventricular end-systolic end diastolic diameter, left ventricular ejection fraction changes and postoperative 24h and 30d adverse cardiac events, bleeding and so on. Results: The level of NT-proBNP in the experimental group was significantly lower than that in the control group (P <0.01) at 1 week after operation. The level of cTnl decreased significantly at 24h and 7d after operation in the experimental group (P <0.01). There was no significant difference in the end-diastolic and diastolic diameters between the two groups at 7 days after operation (P> 0.05). The left ventricular ejection fraction in the experimental group was significantly higher than that of the control group (P <0.05) There was no significant difference in adverse cardiac events and bleeding after 24h and 30d (P> 0.05). Conclusion: The results showed that the early application of tirofiban in patients with acute ST-elevation myocardial infarction PCI improved cardiac function significantly, which can effectively improve patients with left ventricular ejection fraction, and has high safety, it is worth Promote the application.